Journal Article

Understanding the genotoxicity of tamoxifen?

David H. Phillips

in Carcinogenesis

Volume 22, issue 6, pages 839-849
Published in print June 2001 | ISSN: 0143-3334
Published online June 2001 | e-ISSN: 1460-2180 | DOI:
Understanding the genotoxicity of tamoxifen?

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


Tamoxifen is an anti-oestrogenic drug widely used for adjuvant therapy of breast cancer. Its use has caused an increased incidence of endometrial cancer and it is also a potent carcinogen in rat liver. Since the demonstration that tamoxifen forms covalent DNA adducts in rat liver, many investigations of its mechanism of carcinogenic action have focused on the examination of human and animal tissues for the presence of tamoxifen–DNA adducts, the identification of their structures and the determination of the metabolic pathways that lead to their formation. This article reviews the current evidence for genotoxic mechanisms for tamoxifen carcinogenicity, and discusses some inconsistencies in the data.

Keywords: AMS, accelerator mass spectrometry; CIA, chemiluminescence immunoassay; DELFIA, dissociation-enhanced lanthanide fluoroimmunoassay; DHEAS, dehydroisoandrosterone-3-sulphate; SERMs, selective (o)estrogen receptor modulators; tamoxifen, (Z)-1-{4-[2-(dimethylamino) ethoxy]phenyl}-1,2-diphenyl-1-butene.

Journal Article.  9380 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.